Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Receivables - Net: 2010-2024

Historic Receivables - Net for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $13.8 million.

  • China Pharma Holdings' Receivables - Net fell 97.94% to $294,514 in Q3 2025 from the same period last year, while for Sep 2025 it was $294,514, marking a year-over-year decrease of 97.94%. This contributed to the annual value of $13.8 million for FY2024, which is 3.30% down from last year.
  • Per China Pharma Holdings' latest filing, its Receivables - Net stood at $13.8 million for FY2024, which was down 3.30% from $14.3 million recorded in FY2023.
  • In the past 5 years, China Pharma Holdings' Receivables - Net ranged from a high of $14.3 million in FY2023 and a low of $421,531 during FY2022.
  • Over the past 3 years, China Pharma Holdings' median Receivables - Net value was $13.8 million (recorded in 2024), while the average stood at $9.5 million.
  • In the last 5 years, China Pharma Holdings' Receivables - Net plummeted by 41.00% in 2022 and then spiked by 3,290.15% in 2023.
  • Over the past 5 years, China Pharma Holdings' Receivables - Net (Yearly) stood at $501,892 in 2020, then spiked by 42.36% to $714,475 in 2021, then plummeted by 41.00% to $421,531 in 2022, then spiked by 3,290.15% to $14.3 million in 2023, then fell by 3.30% to $13.8 million in 2024.